Global Pharma Business Firm Strengthens Domestic Market Presence By Acquiring 100 Per cent Stake In Bombay Ortho Industries Through Subsidiary
In terms of performance, the stock has delivered a 1-year return of 4.69 per cent and a 3-year return of 45.08 per cent.
Alkem Laboratories Limited acquired 100 per cent of Bombay Ortho Industries Private Limited shares through its subsidiary Alkem Medtech Private Limited. The acquisition was announced on February 7, 2025, and on March 15, 2025, more details were provided before the acquisition was completed on April 16, 2025. The acquisition is in accordance with the terms specified in the share purchase and share subscription agreement dated March 15, 2025. Alkem Laboratories has made Bombay Ortho a wholly owned step-down subsidiary following this strategic move to boost its operational capabilities and market presence in India. This development is in line with Alkem’s broader efforts to strengthen its presence in the pharmaceutical industry, particularly in the domestic market.
DSIJ's 'Value Pick' service recommends long-term stocks based on Value Investing Philosophy. If this interests you, download the service details here.
Alkem Laboratories Limited is one of the major pharmaceutical companies in India with a market share of 4.1 per cent in the Indian domestic formulation market and ranks as the fifth-largest pharmaceutical company in India. The company is a market leader in the anti-infectives segment and also has a significant presence in the gastrointestinal, pain management and vitamins, minerals and nutrients segments. Alkem is also venturing into chronic therapies such as neurology, cardiology and diabetology.
The company generates 70 per cent of its revenue from the domestic market and is a major player in the top therapeutic areas. Abroad, Alkem operates in generics, biosimilars and BioCDMO services with the US being its largest market. It has filed 179 ANDAs in the US with 154 approvals and more than 1,100 dossiers in other international markets. The company has 19 manufacturing facilities, 5 of which are USFDA-approved sites and spends on R&D to pave the way for future growth. It also recently launched Empanorm, a generic empagliflozin, in India at a price that is 80 per cent lower than innovator products.
The stock price of Alkem Laboratories stands at Rs 4,956.5. The company’s stock has recorded a 52-week high of Rs 6,362.5 and a 52-week low of Rs 4,566. Alkem Laboratories has a market capitalisation of Rs 59,262 crore.
In terms of performance, the stock has delivered a 1-year return of 4.69 per cent and a 3-year return of 45.08 per cent. The current price-to-earnings (PE) ratio of the stock is 26.8.
Among the major public shareholders, Kishor Kumar Singh holds a 2.82 per cent stake in the company, followed by Alok Kumar with 2.31 per cent, Ashok Kumar with 2.25 per cent, Deepak Kumar Singh with 2.09 per cent, and Rajesh Kumar with 1.41 per cent.
Disclaimer: The article is for informational purposes only and not investment advice.